Skip to main content
Erschienen in: Endocrine 3/2017

20.07.2017 | Review

The intriguing connections of leptin to hyperparathyroidism

verfasst von: Stergios A. Polyzos, Leonidas Duntas, Jens Bollerslev

Erschienen in: Endocrine | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Leptin has been implicated in bone metabolism, but the association with parathyroid gland function has not been fully clarified. This review aimed to summarize evidence of the association between leptin and hyperparathyroidism, both primary and secondary, elucidating the potential pathophysiologic and therapeutic consequences between leptin and parathyroid hormone, hopefully prompting the design of new studies.

Results

Experimental studies indicate a positive loop between leptin and parathyroid hormone in primary hyperparathyroidism. Dissimilar, parathyroid hormone seems to inhibit leptin expression in severe secondary hyperparathyroidism. Data from clinical studies indicate higher leptin levels in patients with primary hyperparathyroidism than controls, but no association between parathyroid hormone and leptin levels, as well as a minimal or neutral effect of parathyroidectomy on leptin levels in patients with primary hyperparathyroidism. Clinical data on secondary hyperparathyroidism, mainly derived from patients with chronic kidney disease, indicate a potential inverse association between leptin and parathyroid hormone in some, but not all studies. This relationship may be affected by the diversity of morbidity among these patients.

Conclusions

Data from experimental studies suggest a different association between leptin and parathyroid hormone in primary and secondary hyperparathyroidism. Data from clinical studies are conflicting and potentially affected by confounders. More focused, well-designed studies are warranted to elucidate a potential association between leptin and parathyroid hormone, which may have specific clinical implications, i.e., targeting obesity and hyperleptinemia in patients with hyperparathyroidism.
Literatur
1.
Zurück zum Zitat S.A. Polyzos, P. Makras, Z. Efstathiadou, A.D. Anastasilakis, Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Exp. Opin. Investig. Drugs 24, 145–157 (2015)CrossRef S.A. Polyzos, P. Makras, Z. Efstathiadou, A.D. Anastasilakis, Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Exp. Opin. Investig. Drugs 24, 145–157 (2015)CrossRef
3.
Zurück zum Zitat A.A. Khan, D.A. Hanley, R. Rizzoli, J. Bollerslev, J.E. Young, L. Rejnmark, R. Thakker, P. D’Amour, T. Paul, S. Van Uum, M.Z. Shrayyef, D. Goltzman, S. Kaiser, N.E. Cusano, R. Bouillon, L. Mosekilde, A.W. Kung, S.D. Rao, S.K. Bhadada, B.L. Clarke, J. Liu, Q. Duh, E.M. Lewiecki, F. Bandeira, R. Eastell, C. Marcocci, S.J. Silverberg, R. Udelsman, K.S. Davison, J.T. Potts Jr., M.L. Brandi, J.P. Bilezikian, Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos. Int. 28, 1–19 (2017)CrossRefPubMed A.A. Khan, D.A. Hanley, R. Rizzoli, J. Bollerslev, J.E. Young, L. Rejnmark, R. Thakker, P. D’Amour, T. Paul, S. Van Uum, M.Z. Shrayyef, D. Goltzman, S. Kaiser, N.E. Cusano, R. Bouillon, L. Mosekilde, A.W. Kung, S.D. Rao, S.K. Bhadada, B.L. Clarke, J. Liu, Q. Duh, E.M. Lewiecki, F. Bandeira, R. Eastell, C. Marcocci, S.J. Silverberg, R. Udelsman, K.S. Davison, J.T. Potts Jr., M.L. Brandi, J.P. Bilezikian, Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos. Int. 28, 1–19 (2017)CrossRefPubMed
4.
Zurück zum Zitat M.J. Bolland, A.B. Grey, G.D. Gamble, I.R. Reid, Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J. Clin. Endocrinol. Metab. 90, 1525–1530 (2005)CrossRefPubMed M.J. Bolland, A.B. Grey, G.D. Gamble, I.R. Reid, Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J. Clin. Endocrinol. Metab. 90, 1525–1530 (2005)CrossRefPubMed
5.
Zurück zum Zitat M.A. Adam, B.R. Untch, M.E. Danko, S. Stinnett, D. Dixit, J. Koh, J.R. Marks, J.A. Olson Jr., Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 95, 4917–4924 (2010)CrossRefPubMedPubMedCentral M.A. Adam, B.R. Untch, M.E. Danko, S. Stinnett, D. Dixit, J. Koh, J.R. Marks, J.A. Olson Jr., Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 95, 4917–4924 (2010)CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat S.A. Polyzos, C.S. Mantzoros, Leptin in health and disease: facts and expectations at its twentieth anniversary. Metabolism 64, 5–12 (2015)CrossRefPubMed S.A. Polyzos, C.S. Mantzoros, Leptin in health and disease: facts and expectations at its twentieth anniversary. Metabolism 64, 5–12 (2015)CrossRefPubMed
7.
Zurück zum Zitat S.P. Cheng, G.M. Doherty, Y.C. Chang, C.L. Liu, Leptin: the link between overweight and primary hyperparathyroidism? Med. Hypotheses 76, 94–96 (2011)CrossRefPubMed S.P. Cheng, G.M. Doherty, Y.C. Chang, C.L. Liu, Leptin: the link between overweight and primary hyperparathyroidism? Med. Hypotheses 76, 94–96 (2011)CrossRefPubMed
8.
Zurück zum Zitat B.E. Wolfe, D.C. Jimerson, C. Orlova, C.S. Mantzoros, Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clin. Endocrinol. 61, 332–338 (2004)CrossRef B.E. Wolfe, D.C. Jimerson, C. Orlova, C.S. Mantzoros, Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clin. Endocrinol. 61, 332–338 (2004)CrossRef
9.
Zurück zum Zitat M. Dalamaga, S.H. Chou, K. Shields, P. Papageorgiou, S.A. Polyzos, C.S. Mantzoros, Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell. Metab. 18, 29–42 (2013)CrossRefPubMed M. Dalamaga, S.H. Chou, K. Shields, P. Papageorgiou, S.A. Polyzos, C.S. Mantzoros, Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell. Metab. 18, 29–42 (2013)CrossRefPubMed
10.
Zurück zum Zitat S.A. Polyzos, J. Kountouras, C. Zavos, G. Deretzi, The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J. Clin. Gastroenterol. 45, 50–54 (2011)CrossRefPubMed S.A. Polyzos, J. Kountouras, C. Zavos, G. Deretzi, The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J. Clin. Gastroenterol. 45, 50–54 (2011)CrossRefPubMed
11.
Zurück zum Zitat S.A. Polyzos, J. Kountouras, C.S. Mantzoros, Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism 64, 60–78 (2015)CrossRefPubMed S.A. Polyzos, J. Kountouras, C.S. Mantzoros, Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism 64, 60–78 (2015)CrossRefPubMed
12.
Zurück zum Zitat M.A. Tsoukas, O.M. Farr, C.S. Mantzoros, Leptin in congenital and HIV-associated lipodystrophy. Metabolism 64, 47–59 (2015)CrossRefPubMed M.A. Tsoukas, O.M. Farr, C.S. Mantzoros, Leptin in congenital and HIV-associated lipodystrophy. Metabolism 64, 47–59 (2015)CrossRefPubMed
13.
Zurück zum Zitat M. Karakose, M. Caliskan, M.S. Arslan, T. Demirci, S. Karakose, E. Cakal, The impact of parathyroidectomy on serum ADAMTS1, ADAMTS4 levels, insulin resistance, and subclinical cardiovascular disease in primary hyperparathyroidism. Endocrine 55, 283–288 (2017)CrossRefPubMed M. Karakose, M. Caliskan, M.S. Arslan, T. Demirci, S. Karakose, E. Cakal, The impact of parathyroidectomy on serum ADAMTS1, ADAMTS4 levels, insulin resistance, and subclinical cardiovascular disease in primary hyperparathyroidism. Endocrine 55, 283–288 (2017)CrossRefPubMed
14.
Zurück zum Zitat D. Sit, A.K. Kadiroglu, M.E. Yilmaz, I.H. Kara, B. Isikoglu, The prevalence of insulin resistance and its relationship between anemia, secondary hyperparathyroidism, inflammation, and cardiac parameters in chronic hemodialysis patients. Ren. Fail. 27, 403–407 (2005)CrossRefPubMed D. Sit, A.K. Kadiroglu, M.E. Yilmaz, I.H. Kara, B. Isikoglu, The prevalence of insulin resistance and its relationship between anemia, secondary hyperparathyroidism, inflammation, and cardiac parameters in chronic hemodialysis patients. Ren. Fail. 27, 403–407 (2005)CrossRefPubMed
15.
Zurück zum Zitat H.S. Moon, M. Dalamaga, S.Y. Kim, S.A. Polyzos, O.P. Hamnvik, F. Magkos, J. Paruthi, C.S. Mantzoros, Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr. Rev. 34, 377–412 (2013)CrossRefPubMedPubMedCentral H.S. Moon, M. Dalamaga, S.Y. Kim, S.A. Polyzos, O.P. Hamnvik, F. Magkos, J. Paruthi, C.S. Mantzoros, Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr. Rev. 34, 377–412 (2013)CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat J. Upadhyay, O.M. Farr, C.S. Mantzoros, The role of leptin in regulating bone metabolism. Metabolism 64, 105–113 (2015)CrossRefPubMed J. Upadhyay, O.M. Farr, C.S. Mantzoros, The role of leptin in regulating bone metabolism. Metabolism 64, 105–113 (2015)CrossRefPubMed
17.
Zurück zum Zitat X.X. Chen, T. Yang, Roles of leptin in bone metabolism and bone diseases. J. Bone. Miner. Metab. 33, 474–485 (2015)CrossRefPubMed X.X. Chen, T. Yang, Roles of leptin in bone metabolism and bone diseases. J. Bone. Miner. Metab. 33, 474–485 (2015)CrossRefPubMed
18.
Zurück zum Zitat A. Matsunuma, T. Kawane, T. Maeda, S. Hamada, N. Horiuchi, Leptin corrects increased gene expression of renal 25-hydroxyvitamin D3-1 alpha-hydroxylase and -24-hydroxylase in leptin-deficient, ob/ob mice. Endocrinology 145, 1367–1375 (2004)CrossRefPubMed A. Matsunuma, T. Kawane, T. Maeda, S. Hamada, N. Horiuchi, Leptin corrects increased gene expression of renal 25-hydroxyvitamin D3-1 alpha-hydroxylase and -24-hydroxylase in leptin-deficient, ob/ob mice. Endocrinology 145, 1367–1375 (2004)CrossRefPubMed
19.
Zurück zum Zitat K. Tsuji, T. Maeda, T. Kawane, A. Matsunuma, N. Horiuchi, Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J. Bone. Miner. Res. 25, 1711–1723 (2010)CrossRefPubMed K. Tsuji, T. Maeda, T. Kawane, A. Matsunuma, N. Horiuchi, Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J. Bone. Miner. Res. 25, 1711–1723 (2010)CrossRefPubMed
20.
Zurück zum Zitat I. Lopez, C. Pineda, A.I. Raya, M.E. Rodriguez-Ortiz, J.M. Diaz-Tocados, R. Rios, J.M. Rodriguez, E. Aguilera-Tejero, Y. Almaden, Leptin directly stimulates parathyroid hormone secretion. Endocrine 56, 675–678 (2016)CrossRefPubMed I. Lopez, C. Pineda, A.I. Raya, M.E. Rodriguez-Ortiz, J.M. Diaz-Tocados, R. Rios, J.M. Rodriguez, E. Aguilera-Tejero, Y. Almaden, Leptin directly stimulates parathyroid hormone secretion. Endocrine 56, 675–678 (2016)CrossRefPubMed
22.
Zurück zum Zitat D. Hoang, N. Broer, J.A. Sosa, N. Abitbol, X. Yao, F. Li, F. Rivera-Molina, D.K. Toomre, S.A. Roman, G. Sue, S. Kim, A.Y. Li, G.G. Callender, C. Simpson, D. Narayan, Leptin is produced by parathyroid glands and stimulates parathyroid hormone secretion. Ann. Surg. (2016). doi:10.1097/SLA.0000000000002004 D. Hoang, N. Broer, J.A. Sosa, N. Abitbol, X. Yao, F. Li, F. Rivera-Molina, D.K. Toomre, S.A. Roman, G. Sue, S. Kim, A.Y. Li, G.G. Callender, C. Simpson, D. Narayan, Leptin is produced by parathyroid glands and stimulates parathyroid hormone secretion. Ann. Surg. (2016). doi:10.​1097/​SLA.​0000000000002004​
23.
Zurück zum Zitat Y. Jiang, J. Zhang, Y. Yuan, X. Zha, C. Xing, C. Shen, Z. Shen, C. Qin, M. Zeng, G. Yang, H. Mao, B. Zhang, X. Yu, B. Sun, C. Ouyang, X. Xu, Y. Ge, J. Wang, L. Zhang, C. Cheng, C. Yin, J. Zhang, H. Chen, H. Ma, N. Wang, Association of increased serum leptin with ameliorated anemia and malnutrition in stage 5 chronic kidney disease patients after parathyroidectomy. Sci. Rep. 6, 27918 (2016)CrossRefPubMedPubMedCentral Y. Jiang, J. Zhang, Y. Yuan, X. Zha, C. Xing, C. Shen, Z. Shen, C. Qin, M. Zeng, G. Yang, H. Mao, B. Zhang, X. Yu, B. Sun, C. Ouyang, X. Xu, Y. Ge, J. Wang, L. Zhang, C. Cheng, C. Yin, J. Zhang, H. Chen, H. Ma, N. Wang, Association of increased serum leptin with ameliorated anemia and malnutrition in stage 5 chronic kidney disease patients after parathyroidectomy. Sci. Rep. 6, 27918 (2016)CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat E. Delfini, L. Petramala, C. Caliumi, D. Cotesta, G. De Toma, G. Cavallaro, G. Panzironi, D. Diacinti, S. Minisola, D.E. E, G.F. Mazzuoli, C. Letizia, Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism 56, 30–36 (2007)CrossRefPubMed E. Delfini, L. Petramala, C. Caliumi, D. Cotesta, G. De Toma, G. Cavallaro, G. Panzironi, D. Diacinti, S. Minisola, D.E. E, G.F. Mazzuoli, C. Letizia, Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism 56, 30–36 (2007)CrossRefPubMed
25.
Zurück zum Zitat S.K. Bhadada, A. Bhansali, V.N. Shah, D.S. Rao, Changes in serum leptin and adiponectin concentrations and insulin resistance after curative parathyroidectomy in moderate to severe primary hyperparathyroidism. Singapore Med. J. 52, 890–893 (2011)PubMed S.K. Bhadada, A. Bhansali, V.N. Shah, D.S. Rao, Changes in serum leptin and adiponectin concentrations and insulin resistance after curative parathyroidectomy in moderate to severe primary hyperparathyroidism. Singapore Med. J. 52, 890–893 (2011)PubMed
26.
Zurück zum Zitat D.A. de Luis, G.D. Soto, R. Conde, O. Izaola, B. de la Fuente, Relation of leptin and adiponectin with cardiovascular risk factors, intact parathormone, and vitamin D levels in patients with primary hyperparathyroidism. J. Clin. Lab. Anal. 26, 398–402 (2012)CrossRef D.A. de Luis, G.D. Soto, R. Conde, O. Izaola, B. de la Fuente, Relation of leptin and adiponectin with cardiovascular risk factors, intact parathormone, and vitamin D levels in patients with primary hyperparathyroidism. J. Clin. Lab. Anal. 26, 398–402 (2012)CrossRef
27.
Zurück zum Zitat D. Hoang, N. Broer, S.A. Roman, X. Yao, N. Abitbol, F. Li, J.A. Sosa, G.R. Sue, A.T. DeWan, M.L. Wong, J. Licinio, C. Simpson, A.Y. Li, N. Pizzoferrato, D. Narayan, Leptin signaling and hyperparathyroidism: clinical and genetic associations. J. Am. Coll. Surg. 218, 1239–1250 (2014). e1234CrossRefPubMed D. Hoang, N. Broer, S.A. Roman, X. Yao, N. Abitbol, F. Li, J.A. Sosa, G.R. Sue, A.T. DeWan, M.L. Wong, J. Licinio, C. Simpson, A.Y. Li, N. Pizzoferrato, D. Narayan, Leptin signaling and hyperparathyroidism: clinical and genetic associations. J. Am. Coll. Surg. 218, 1239–1250 (2014). e1234CrossRefPubMed
28.
Zurück zum Zitat J. Bollerslev, T. Rosen, C.L. Mollerup, J. Nordenstrom, M. Baranowski, C. Franco, Y. Pernow, G.A. Isaksen, K. Godang, T. Ueland, S. Jansson, S.S. Group, Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94, 2255–2261 (2009)CrossRef J. Bollerslev, T. Rosen, C.L. Mollerup, J. Nordenstrom, M. Baranowski, C. Franco, Y. Pernow, G.A. Isaksen, K. Godang, T. Ueland, S. Jansson, S.S. Group, Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94, 2255–2261 (2009)CrossRef
29.
Zurück zum Zitat F. Kokot, J. Chudek, H. Karkoszka, M. Adamczak, A. Wiecek, D. Klimek, Does PTH influence leptin concentration in haemodialysed uraemic patients? Nephron 82, 372–373 (1999)CrossRefPubMed F. Kokot, J. Chudek, H. Karkoszka, M. Adamczak, A. Wiecek, D. Klimek, Does PTH influence leptin concentration in haemodialysed uraemic patients? Nephron 82, 372–373 (1999)CrossRefPubMed
30.
Zurück zum Zitat R. Pecoits-Filho, L. Nordfors, O. Heimburger, B. Lindholm, B. Anderstam, A. Marchlewska, P. Stenvinkel, Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. Eur. J. Clin. Invest. 32, 811–817 (2002)CrossRefPubMed R. Pecoits-Filho, L. Nordfors, O. Heimburger, B. Lindholm, B. Anderstam, A. Marchlewska, P. Stenvinkel, Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. Eur. J. Clin. Invest. 32, 811–817 (2002)CrossRefPubMed
31.
Zurück zum Zitat G. Coen, P. Ballanti, M.S. Fischer, A. Balducci, S. Calabria, L. Colamarco, G.Di Zazzo, F. Lifrieri, M. Manni, D. Sardella, I. Nofroni, E. Bonucci, Serum leptin in dialysis renal osteodystrophy. Am. J. Kidney Dis. 42, 1036–1042 (2003)CrossRefPubMed G. Coen, P. Ballanti, M.S. Fischer, A. Balducci, S. Calabria, L. Colamarco, G.Di Zazzo, F. Lifrieri, M. Manni, D. Sardella, I. Nofroni, E. Bonucci, Serum leptin in dialysis renal osteodystrophy. Am. J. Kidney Dis. 42, 1036–1042 (2003)CrossRefPubMed
32.
Zurück zum Zitat J. Axelsson, A.R. Qureshi, O. Heimburger, B. Lindholm, P. Stenvinkel, P. Barany, Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am. J. Kidney Dis. 46, 628–634 (2005)CrossRefPubMed J. Axelsson, A.R. Qureshi, O. Heimburger, B. Lindholm, P. Stenvinkel, P. Barany, Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am. J. Kidney Dis. 46, 628–634 (2005)CrossRefPubMed
33.
Zurück zum Zitat C.P. Kovesdy, M.Z. Molnar, M.E. Czira, A. Rudas, A. Ujszaszi, L. Rosivall, M. Szathmari, A. Covic, A. Keszei, G. Beko, P. Lakatos, J. Kosa, I. Mucsi, Associations between serum leptin level and bone turnover in kidney transplant recipients. Clin. J. Am. Soc. Nephrol. 5, 2297–2304 (2010)CrossRefPubMedCentral C.P. Kovesdy, M.Z. Molnar, M.E. Czira, A. Rudas, A. Ujszaszi, L. Rosivall, M. Szathmari, A. Covic, A. Keszei, G. Beko, P. Lakatos, J. Kosa, I. Mucsi, Associations between serum leptin level and bone turnover in kidney transplant recipients. Clin. J. Am. Soc. Nephrol. 5, 2297–2304 (2010)CrossRefPubMedCentral
34.
Zurück zum Zitat T.A. Ghonemy, E.M. Salim, M. Atia, A. Fekry, K. Shawky, Serum leptin and bone mineral density in hemodialysis patients with or without liver diseases. Arab J. Nephrol. Transplant. 4, 131–136 (2011)CrossRefPubMed T.A. Ghonemy, E.M. Salim, M. Atia, A. Fekry, K. Shawky, Serum leptin and bone mineral density in hemodialysis patients with or without liver diseases. Arab J. Nephrol. Transplant. 4, 131–136 (2011)CrossRefPubMed
35.
Zurück zum Zitat O. Ulutas, H. Taskapan, M.C. Taskapan, I. Temel, Vitamin D deficiency, insulin resistance, serum adipokine, and leptin levels in peritoneal dialysis patients. Int. Urol. Nephrol. 45, 879–884 (2013)CrossRefPubMed O. Ulutas, H. Taskapan, M.C. Taskapan, I. Temel, Vitamin D deficiency, insulin resistance, serum adipokine, and leptin levels in peritoneal dialysis patients. Int. Urol. Nephrol. 45, 879–884 (2013)CrossRefPubMed
36.
Zurück zum Zitat Y. Jiang, Z. Shen, J. Zhang, C. Xing, X. Zha, C. Shen, M. Zeng, G. Yang, H. Mao, B. Zhang, X. Yu, B. Sun, C. Ouyang, Y. Ge, L. Zhang, C. Cheng, J. Zhang, C. Yin, H. Chen, N. Wang, Parathyroidectomy increases heart rate variability and leptin levels in patients with stage 5 chronic kidney disease. Am. J. Nephrol. 44, 245–254 (2016)CrossRefPubMed Y. Jiang, Z. Shen, J. Zhang, C. Xing, X. Zha, C. Shen, M. Zeng, G. Yang, H. Mao, B. Zhang, X. Yu, B. Sun, C. Ouyang, Y. Ge, L. Zhang, C. Cheng, J. Zhang, C. Yin, H. Chen, N. Wang, Parathyroidectomy increases heart rate variability and leptin levels in patients with stage 5 chronic kidney disease. Am. J. Nephrol. 44, 245–254 (2016)CrossRefPubMed
37.
Zurück zum Zitat A.C. Baxmann, V.B. Menon, J.O. Medina-Pestana, A.B. Carvalho, I.P. Heilberg, Overweight and body fat are predictors of hypovitaminosis D in renal transplant patients. Clin. Kidney J. 8, 49–53 (2015)CrossRefPubMed A.C. Baxmann, V.B. Menon, J.O. Medina-Pestana, A.B. Carvalho, I.P. Heilberg, Overweight and body fat are predictors of hypovitaminosis D in renal transplant patients. Clin. Kidney J. 8, 49–53 (2015)CrossRefPubMed
38.
Zurück zum Zitat J.P. Tsai, M.C. Lee, Y.C. Chen, G.J. Ho, M.H. Shih, B.G. Hsu, Hyperleptinemia is a risk factor for the development of central arterial stiffness in kidney transplant patients. Transplant. Proc. 47, 1825–1830 (2015)CrossRefPubMed J.P. Tsai, M.C. Lee, Y.C. Chen, G.J. Ho, M.H. Shih, B.G. Hsu, Hyperleptinemia is a risk factor for the development of central arterial stiffness in kidney transplant patients. Transplant. Proc. 47, 1825–1830 (2015)CrossRefPubMed
39.
Zurück zum Zitat T. Hryszko, S. Brzosko, A. Rydzewska-Rosolowska, E. Koc-Zorawska, B. Naumnik, M. Mysliwiec, Effect of secondary hyperparathyroidism treatment with cinacalcet on selected adipokines and markers of endothelial injury in hemodialysis patients: a preliminary report. Pol. Arch. Med. Wewn. 122, 148–153 (2012) T. Hryszko, S. Brzosko, A. Rydzewska-Rosolowska, E. Koc-Zorawska, B. Naumnik, M. Mysliwiec, Effect of secondary hyperparathyroidism treatment with cinacalcet on selected adipokines and markers of endothelial injury in hemodialysis patients: a preliminary report. Pol. Arch. Med. Wewn. 122, 148–153 (2012)
40.
Zurück zum Zitat A. Polymeris, K. Doumouchtsis, E. Grapsa, Bone mineral density and bone metabolism in hemodialysis patients. Correlation with PTH, 25OHD3 and leptin. Nefrologia 32, 73–78 (2012)PubMed A. Polymeris, K. Doumouchtsis, E. Grapsa, Bone mineral density and bone metabolism in hemodialysis patients. Correlation with PTH, 25OHD3 and leptin. Nefrologia 32, 73–78 (2012)PubMed
41.
Zurück zum Zitat F. Ahmadi, S. Salari, S. Maziar, F. Esfahanian, Z. Khazaeipour, N. Ranjbarnovin, Relationship between serum leptin levels and bone mineral density and bone metabolic markers in patients on hemodialysis. Saudi J. Kidney. Dis. Transpl. 24, 41–47 (2013)CrossRefPubMed F. Ahmadi, S. Salari, S. Maziar, F. Esfahanian, Z. Khazaeipour, N. Ranjbarnovin, Relationship between serum leptin levels and bone mineral density and bone metabolic markers in patients on hemodialysis. Saudi J. Kidney. Dis. Transpl. 24, 41–47 (2013)CrossRefPubMed
42.
Zurück zum Zitat M. Ghorban-Sabbagh, F. Nazemian, M. Naghibi, M.T. Shakeri, S. Ahmadi-Simab, R. Javidi-Dasht-Bayaz, Correlation between serum leptin and bone mineral density in hemodialysis patients. J. Renal. Inj. Prev. 5, 112–117 (2016)CrossRefPubMedPubMedCentral M. Ghorban-Sabbagh, F. Nazemian, M. Naghibi, M.T. Shakeri, S. Ahmadi-Simab, R. Javidi-Dasht-Bayaz, Correlation between serum leptin and bone mineral density in hemodialysis patients. J. Renal. Inj. Prev. 5, 112–117 (2016)CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat C. Zoccali, V. Panuccio, G. Tripepi, S. Cutrupi, P. Pizzini, F. Mallamaci, Leptin and biochemical markers of bone turnover in dialysis patients. J. Nephrol. 17, 253–260 (2004) C. Zoccali, V. Panuccio, G. Tripepi, S. Cutrupi, P. Pizzini, F. Mallamaci, Leptin and biochemical markers of bone turnover in dialysis patients. J. Nephrol. 17, 253–260 (2004)
44.
Zurück zum Zitat S.A. Polyzos, C.S. Mantzoros, Nonalcoholic fatty future disease. Metabolism 65, 1007–1016 (2016)CrossRefPubMed S.A. Polyzos, C.S. Mantzoros, Nonalcoholic fatty future disease. Metabolism 65, 1007–1016 (2016)CrossRefPubMed
45.
Zurück zum Zitat S.A. Polyzos, K.N. Aronis, J. Kountouras, D.D. Raptis, M.F. Vasiloglou, C.S. Mantzoros, Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 59, 30–43 (2016)CrossRefPubMed S.A. Polyzos, K.N. Aronis, J. Kountouras, D.D. Raptis, M.F. Vasiloglou, C.S. Mantzoros, Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 59, 30–43 (2016)CrossRefPubMed
46.
Zurück zum Zitat K. Liu, P. Liu, R. Liu, X. Wu, M. Cai, Relationship between serum leptin levels and bone mineral density: a systematic review and meta-analysis. Clin. Chim. Acta. 444, 260–263 (2015)CrossRefPubMed K. Liu, P. Liu, R. Liu, X. Wu, M. Cai, Relationship between serum leptin levels and bone mineral density: a systematic review and meta-analysis. Clin. Chim. Acta. 444, 260–263 (2015)CrossRefPubMed
47.
Zurück zum Zitat S.A. Polyzos, J. Kountouras, C.S. Mantzoros, Adipose tissue, obesity and nonalcoholic fatty liver disease. Minerva Endocrinol. (2016) [epub ahead of print] S.A. Polyzos, J. Kountouras, C.S. Mantzoros, Adipose tissue, obesity and nonalcoholic fatty liver disease. Minerva Endocrinol. (2016) [epub ahead of print]
48.
Zurück zum Zitat G. Thomas, A.R. Sehgal, S.R. Kashyap, T.R. Srinivas, J.P. Kirwan, S.D. Navaneethan, Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 6, 2364–2373 (2011)CrossRefPubMedPubMedCentral G. Thomas, A.R. Sehgal, S.R. Kashyap, T.R. Srinivas, J.P. Kirwan, S.D. Navaneethan, Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 6, 2364–2373 (2011)CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat K.A. Toulis, A.D. Anastasilakis, S.A. Polyzos, P. Makras, Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. Hormones 10, 174–195 (2011)CrossRefPubMed K.A. Toulis, A.D. Anastasilakis, S.A. Polyzos, P. Makras, Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. Hormones 10, 174–195 (2011)CrossRefPubMed
50.
Zurück zum Zitat E.G. Abate, B.L. Clarke, Review of Hypoparathyroidism. Front. Endocrinol. 7, 172 (2016) E.G. Abate, B.L. Clarke, Review of Hypoparathyroidism. Front. Endocrinol. 7, 172 (2016)
51.
Zurück zum Zitat J.P. Foo, S.A. Polyzos, A.D. Anastasilakis, S. Chou, C.S. Mantzoros, The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wnt inhibitors in young women with hypothalamic amenorrhea. J. Clin. Endocrinol. Metab. 99, E2252–E2258 (2014)CrossRefPubMedPubMedCentral J.P. Foo, S.A. Polyzos, A.D. Anastasilakis, S. Chou, C.S. Mantzoros, The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wnt inhibitors in young women with hypothalamic amenorrhea. J. Clin. Endocrinol. Metab. 99, E2252–E2258 (2014)CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat J.D. Christensen, A.O. Lungu, E. Cochran, M.T. Collins, R.I. Gafni, J.C. Reynolds, K.I. Rother, P. Gorden, R.J. Brown, Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. J. Clin. Endocrinol. Metab. 99, E1493–E1500 (2014)CrossRefPubMedPubMedCentral J.D. Christensen, A.O. Lungu, E. Cochran, M.T. Collins, R.I. Gafni, J.C. Reynolds, K.I. Rother, P. Gorden, R.J. Brown, Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. J. Clin. Endocrinol. Metab. 99, E1493–E1500 (2014)CrossRefPubMedPubMedCentral
53.
Zurück zum Zitat T. Harslof, T. Sikjaer, L. Sorensen, S.B. Pedersen, L. Mosekilde, B.L. Langdahl, L. Rejnmark, The effect of treatment with pth on undercarboxylated osteocalcin and energy metabolism in hypoparathyroidism. J. Clin. Endocrinol. Metab. 100, 2758–2762 (2015)CrossRefPubMed T. Harslof, T. Sikjaer, L. Sorensen, S.B. Pedersen, L. Mosekilde, B.L. Langdahl, L. Rejnmark, The effect of treatment with pth on undercarboxylated osteocalcin and energy metabolism in hypoparathyroidism. J. Clin. Endocrinol. Metab. 100, 2758–2762 (2015)CrossRefPubMed
54.
Zurück zum Zitat A.L. Schafer, D.E. Sellmeyer, A.V. Schwartz, C.J. Rosen, E. Vittinghoff, L. Palermo, J.P. Bilezikian, D.M. Shoback, D.M. Black, Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J. Clin. Endocrinol. Metab. 96, E1982–E1989 (2011)CrossRefPubMedPubMedCentral A.L. Schafer, D.E. Sellmeyer, A.V. Schwartz, C.J. Rosen, E. Vittinghoff, L. Palermo, J.P. Bilezikian, D.M. Shoback, D.M. Black, Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J. Clin. Endocrinol. Metab. 96, E1982–E1989 (2011)CrossRefPubMedPubMedCentral
55.
Zurück zum Zitat E. Passeri, E. Dozio, M. Mendola, E. Costa, F. Bandera, M.M. Corsi Romanelli, S. Corbetta, Treatment with teriparatide might be associated with cardiometabolic changes in postmenopausal severe osteoporotic women. J. Biol. Regul. Homeost. Agents 29, 931–940 (2015)PubMed E. Passeri, E. Dozio, M. Mendola, E. Costa, F. Bandera, M.M. Corsi Romanelli, S. Corbetta, Treatment with teriparatide might be associated with cardiometabolic changes in postmenopausal severe osteoporotic women. J. Biol. Regul. Homeost. Agents 29, 931–940 (2015)PubMed
56.
Zurück zum Zitat M. Maetani, G. Maskarinec, A.A. Franke, R.V. Cooney, Association of leptin, 25-hydroxyvitamin D, and parathyroid hormone in women. Nutr. Cancer 61, 225–231 (2009)CrossRefPubMedPubMedCentral M. Maetani, G. Maskarinec, A.A. Franke, R.V. Cooney, Association of leptin, 25-hydroxyvitamin D, and parathyroid hormone in women. Nutr. Cancer 61, 225–231 (2009)CrossRefPubMedPubMedCentral
Metadaten
Titel
The intriguing connections of leptin to hyperparathyroidism
verfasst von
Stergios A. Polyzos
Leonidas Duntas
Jens Bollerslev
Publikationsdatum
20.07.2017
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1374-6

Weitere Artikel der Ausgabe 3/2017

Endocrine 3/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.